Allied Market Research
Loading...
0
New
New

Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, and Human), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others), and End User (Hospitals, Research Institutes, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

A11789
Pages: 245
Jun 2021 | 633 Views
   
Author(s) : Sushant Terdale , Onkar Sumant
Tables: 118
Charts: 59
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Monoclonal Antibodies Market

Request Now !

Monoclonal Antibodies Market Outlook 2030:

The global monoclonal antibodies market size was valued at $146,642 million in 2020, and is projected to reach $390,582 million by 2030, registering a CAGR of 10.2% from 2021 to 2030.

Monoclonal antibody (mAb) therapy is a form of immunotherapy that utilizes monoclonal antibodies to attach mono specifically to specific proteins or cells. Monoclonal antibodies are replicas of a unique parental cell derived from identical immune cells. These antibodies can bind to a particular antigen when administered, as they have monovalent affinity. Monoclonal antibodies serve as an important tool to detect or purify substances, owing to their site specificity; thus, they have important end use in biochemistry, molecular biology, and medicine. 

Global-Monoclonal-Antibodies-Market

Get more information on this report : Request Sample Pages

Increase in prevalence of cancer, increase in demand for cost-efficient biosimilar monoclonal antibodies, high demand for biologics, and increase in R&D activities in genomics coupled with the introduction of technologically advanced genetic platforms, such as next-generation sequencing are the major factors that drive the growth of the market. In addition, surge in research collaborations for the development of robust drugs pipeline, rise in awareness levels among patients & physicians pertaining to the applications of monoclonal antibodies (mAb) therapy, and increase in approval of blockbuster mAbs for a variety of applications further boost the growth of the market. Moreover, employment of advanced genetic engineering technology in mAbs production, presence of a well-established healthcare infrastructure, government support in infection control & management, and increase in incidence of lifestyle associated diseases are the other factors that fuel the growth of market. However, poor demand in underdeveloped countries is expected to restrain the growth of the monoclonal antibodies market. Conversely, growth opportunities in emerging markets are expected to offer lucrative opportunities during the forecast period. 

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a positive impact on the monoclonal antibodies market for the development of monoclonal antibodies therapy to treat COVID-19. The recognition of the urgent necessity for treatments available on a global scale has encouraged the rapid development of a large number of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralizing monoclonal antibodies (mAbs). Thus, COVID-19 infection uplifted growth and opportunities for key players of monoclonal antibodies during the forecast period.

Monoclonal Antibodies Market
By Source

Your browser does not support the canvas element.

Human segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Monoclonal Antibodies Market Segmentation  

The monoclonal antibodies market is segmented on the basis of source, indication, end user, and region. On the basis of source, the market is categorized into murine, chimeric, humanized, and human. By indication, the market is divided into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others. The cancer segment is further classified into breast cancer, colorectal cancer, lung cancer, ovarian cancer, and others. By end user, the market is fragmented into hospitals, research institutes, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Monoclonal Antibodies Market
By End User

Your browser does not support the canvas element.

Hospitals segment held a dominant position in 2020 and will continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment review 

On the basis of source, the human segment is the major revenue contributor, and is projected to grow significantly during the forecast period. Rise in integration of advanced technology such as phage or yeast display, and transgenic mice, for human monoclonal antibodies generation, increase in usage for treatment of various chronic diseases, employment of advanced genetic engineering technology, increase in government support in infection control & management, and increase in number of product approvals are the major factors that drive the growth of the market.

Monoclonal Antibodies Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific would exhibit the highest CAGR of 11.7% during 2021-2030.

Get more information on this report : Request Sample Pages

By indication, the cancer segment is the major shareholder in the monoclonal antibodies market, owing to increase in prevalence of cancer, and rise in adoption of monoclonal antibodies in cancer treatment. In addition, surge in number of drug pipelines, surge in demand for biosimilar monoclonal antibodies, and increase in awareness level among the patient population regarding cancer treatment procedures further drive the growth of the market

Snapshot of Asia-Pacific monoclonal antibodies market  

Asia-Pacific presents lucrative opportunities for key players operating in the monoclonal antibodies market, owing to increase in number of initiatives and enhanced investments from governments for overall R&D of monoclonal antibody therapy and rise in number of product approvals. In addition, ongoing innovations in monoclonal antibodies, availability of advanced healthcare systems, and significant surge in demand for advanced healthcare facilities contribute toward the growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the monoclonal antibodies market in the region

List Of Key Companies:

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis
  • Pfizer

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the monoclonal antibodies market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers monoclonal antibodies market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global monoclonal antibodies market growth.

Key Market Segments

By Source

  • Murine
  • Chimeric
  • Humanized
  • Human 

By Indication

  • Cancer
    • Breast cancer
    • Colorectal cancer 
    • Lung cancer
    • Ovarian cancer
    • Others
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Others

By End User

  • Hospitals
  • Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description 
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in prevalence of various cancer types
3.5.1.2.Increase in demand of cost-efficient biosimilar monoclonal antibodies
3.5.1.3.Upsurge in likelihood of epidemic or pandemic outbreaks

3.5.2.Restraint

3.5.2.1.Poor demand in underdeveloped countries

3.5.3.Opportunities

3.5.3.1.Growth opportunities in emerging markets

3.5.4.Impact analysis

3.6.Covid-19 Impact analysis on monoclonal antibodies market

CHAPTER 4:MONOCLONAL ANTIBODIES MARKET, BY SOURCE

4.1.Overview

4.1.1.Market size and forecast

4.2.Murine

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Chimeric

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Humanized

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Human

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:MONOCLONAL ANTIBODIES MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Cancer

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by type

5.2.3.1.Breast cancer

5.2.3.1.1.Market size and forecast

5.2.3.2.Colorectal cancer

5.2.3.2.1.Market size and forecast

5.2.3.3.Lung cancer

5.2.3.3.1.Market size and forecast

5.2.3.4.Ovarian cancer

5.2.3.4.1.Market size and forecast

5.2.3.5.Others

5.2.3.5.1.Market size and forecast

5.3.Autoimmune diseases

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Inflammatory diseases

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Infectious diseases

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Others

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

CHAPTER 6:MONOCLONAL ANTIBODIES MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Research institutes

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Others

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:MONOCLONAL ANTIBODIES MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. monoclonal antibodies market, by source
7.2.2.1.2.U.S. monoclonal antibodies market, by indication
7.2.2.1.3.U.S. monoclonal antibodies market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada monoclonal antibodies market, by source
7.2.2.2.2.Canada monoclonal antibodies market, by indication
7.2.2.2.3.Canada monoclonal antibodies market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico monoclonal antibodies market, by source
7.2.2.3.2.Mexico monoclonal antibodies market, by indication
7.2.2.3.3.Mexico monoclonal antibodies market, by end user

7.2.3.North America market size and forecast, by source
7.2.4.North America market size and forecast, by indication
7.2.5.North America market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany monoclonal antibodies market, by source
7.3.2.1.2.Germany monoclonal antibodies market, by indication
7.3.2.1.3.Germany monoclonal antibodies market, by end user

7.3.2.2.France

7.3.2.2.1.France monoclonal antibodies market, by source
7.3.2.2.2.France monoclonal antibodies market, by indication
7.3.2.2.3.France monoclonal antibodies market, by end user

7.3.2.3.UK

7.3.2.3.1.UK monoclonal antibodies market, by source
7.3.2.3.2.UK monoclonal antibodies market, by indication
7.3.2.3.3.UK monoclonal antibodies market, by end user

7.3.2.4.Italy

7.3.2.4.1.Italy monoclonal antibodies market, by source
7.3.2.4.2.Italy monoclonal antibodies market, by indication
7.3.2.4.3.Italy monoclonal antibodies market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain monoclonal antibodies market, by source
7.3.2.5.2.Spain monoclonal antibodies market, by indication
7.3.2.5.3.Spain monoclonal antibodies market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe monoclonal antibodies market, by source
7.3.2.6.2.Rest of Europe monoclonal antibodies market, by indication
7.3.2.6.3.Rest of Europe monoclonal antibodies market, by end user

7.3.3.Europe market size and forecast, by source
7.3.4.Europe market size and forecast, by indication
7.3.5.Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan monoclonal antibodies market, by source
7.4.2.1.2.Japan monoclonal antibodies market, by indication
7.4.2.1.3.Japan monoclonal antibodies market, by end user

7.4.2.2.China

7.4.2.2.1.China monoclonal antibodies market, by source
7.4.2.2.2.China monoclonal antibodies market, by indication
7.4.2.2.3.China monoclonal antibodies market, by end user

7.4.2.3.Australia

7.4.2.3.1.Australia monoclonal antibodies market, by source
7.4.2.3.2.Australia monoclonal antibodies market, by indication
7.4.2.3.3.Australia monoclonal antibodies market, by end user

7.4.2.4.India

7.4.2.4.1.India monoclonal antibodies market, by source
7.4.2.4.2.India monoclonal antibodies market, by indication
7.4.2.4.3.India monoclonal antibodies market, by end user

7.4.2.5.South Korea

7.4.2.5.1.South Korea monoclonal antibodies market, by source
7.4.2.5.2.South Korea monoclonal antibodies market, by indication
7.4.2.5.3.South Korea monoclonal antibodies market, by end user

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific monoclonal antibodies market, by source
7.4.2.6.2.Rest of Asia-Pacific monoclonal antibodies market, by indication
7.4.2.6.3.Rest of Asia-Pacific monoclonal antibodies market, by end user

7.4.3.Asia-Pacific market size and forecast, by source
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil monoclonal antibodies market, by source
7.5.2.1.2.Brazil monoclonal antibodies market, by indication
7.5.2.1.3.Brazil monoclonal antibodies market, by end user

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia monoclonal antibodies market, by source
7.5.2.2.2.Saudi Arabia monoclonal antibodies market, by indication
7.5.2.2.3.Saudi Arabia monoclonal antibodies market, by end user

7.5.2.3.South Africa

7.5.2.3.1.South Africa monoclonal antibodies market, by source
7.5.2.3.2.South Africa monoclonal antibodies market, by indication
7.5.2.3.3.South Africa monoclonal antibodies market, by end user

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA monoclonal antibodies market, by source
7.5.2.4.2.Rest of LAMEA monoclonal antibodies market, by indication
7.5.2.4.3.Rest of LAMEA monoclonal antibodies market, by end user

7.5.3.LAMEA market size and forecast, by source
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.Abbott Laboratories

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.Amgen Inc

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product Portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.AstraZeneca PLC.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product Portfolio
8.3.5.Business performance

8.4.Bayer AG.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product Portfolio
8.4.5.Business performance

8.5.Eli Lily and Company.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.GlaxoSmithKline plc

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.Johnson & Johnson

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.Merck & Co., Inc.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.Novartis AG

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.PFIZER INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020-2030 ($MILLION)
TABLE 02.MURINE MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.CHIMERIC MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.HUMANIZED MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.HUMAN MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 07.MONOCLONAL ANTIBODIES MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 08.MONOCLONAL ANTIBODIES MARKET FOR CANCER, BY TYPE, 2020–2030 ($MILLION)
TABLE 09.MONOCLONAL ANTIBODIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 10.MONOCLONAL ANTIBODIES MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 11.MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 12.MONOCLONAL ANTIBODIES MARKET FOR OTHER INDICATIONS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14.MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.MONOCLONAL ANTIBODIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030 ($MILLION)
TABLE 16.MONOCLONAL ANTIBODIES MARKET FOR OTHER END USER, BY REGION, 2020-2030 ($MILLION)
TABLE 17.MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 20.U.S. MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 21.U.S. MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 22.CANADA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 23.CANADA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 24.CANADA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.MEXICO MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 26.MEXICO MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 27.MEXICO MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.EUROPE MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 32.GERMANY MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 33.GERMANY MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 34.GERMANY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 35.FRANCE MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 36.FRANCE MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 37.FRANCE MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.UK MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 39.UK MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 40.UK MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.ITALY MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 42.ITALY MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 43.ITALY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.SPAIN MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 45.SPAIN MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 46.SPAIN MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 48.REST OF EUROPE MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 50.EUROPE MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 51.EUROPE MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 52.EUROPE MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.JAPAN MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 55.JAPAN MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 56.JAPAN MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 57.CHINA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 58.CHINA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 59.CHINA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 63.INDIA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 64.INDIA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 65.INDIA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 67.SOUTH KOREA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 72.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 73.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 74.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 75.LAMEA MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 76.BRAZIL MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 77.BRAZIL MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 78.BRAZIL MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 80.SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 83.SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 86.REST OF LAMEA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 88.LAMEA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 89.LAMEA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 90.LAMEA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 91.ABBOTT: COMPANY SNAPSHOT
TABLE 92.ABBOTT: OPERATING SEGMENTS
TABLE 93.ABBOTT: PRODUCT PORTFOLIO
TABLE 94.AMGEN: COMPANY SNAPSHOT
TABLE 95.AMGEN: OPERATING SEGMENTS
TABLE 96.AMGEN: PRODUCT PORTFOLIO
TABLE 97.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 98.ASTRAZENECA: BUSINESS SEGMENT
TABLE 99.BAYER: COMPANY SNAPSHOT
TABLE 100.BAYER: BUSINESS SEGMENT
TABLE 101.ELI LILLY: COMPANY SNAPSHOT
TABLE 102.ELI LILLY: OPERATING SEGMENTS
TABLE 103.ELI LILLY: PRODUCT PORTFOLIO
TABLE 104.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 105.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 106.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 107.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 108.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 109.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 110.MERCK: COMPANY SNAPSHOT
TABLE 111.MERCK: OPERATING SEGMENTS
TABLE 112.MERCK: PRODUCT PORTFOLIO
TABLE 113.NOVARTIS: COMPANY SNAPSHOT
TABLE 114.NOVARTIS: OPERATING SEGMENTS
TABLE 115.NOVARTIS: PRODUCT PORTFOLIO
TABLE 116.PFIZER: COMPANY SNAPSHOT
TABLE 117.PFIZER: OPERATING SEGMENTS
TABLE 118.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.MONOCLONAL ANTIBODIES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF MURINE MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF CHIMERIC MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HUMANIZED MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF HUMAN MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR CANCER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.BREAST CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 19.COLORECTAL CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 20.LUNG CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 21.OVARIAN CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 22.OTHER CANCER TYPE MARKET, 2020–2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 28.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR OTHER END USER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 30.ABBOTT: NET SALES, 2018–2020 ($MILLION)

FIGURE 31.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.NET SALES, 2018–2020 ($MILLION)
FIGURE 34.AMGEN: NET SALES BY DIVISION, 2020 (%)
FIGURE 35.AMGEN: NET SALES BY REGION, 2020 (%)
FIGURE 36.NET SALES, 2018–2020 ($MILLION)
FIGURE 37.ASTRAZENECA REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 38.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.NET SALES, 2018–2020 ($MILLION)
FIGURE 40.BAYER REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 41.BAYER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.NET SALES, 2018–2020 ($MILLION)
FIGURE 43.ELI LILLY REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 44.ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.GLAXOSMITHKLINE: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47.GLAXOSMITHKLINE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 48.NET SALES, 2018–2020 ($MILLION)
FIGURE 49.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 51.NET SALES, 2018–2020 ($MILLION)
FIGURE 52.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 53.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 54.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 55.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 56.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 57.PFIZER NET SALES, 2019–2020 ($MILLION)
FIGURE 58.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 59.PFIZER: REVENUE SHARE BY REGION, 2020 (%)

 
 

Monoclonal antibodies are laboratory-produced molecules that are similar to human antibodies in the immune system. The monoclonal antibodies can be made by four sources such as murine, chimeric, humanized, and human. The monoclonal antibodies are developed with the generation of hybridomas.

Factors, such as rise in number of chronic diseases across the globe, rise in public awareness toward minimal adverse effects by monoclonal antibody therapies over drugs & chemotherapy for cancer treatment, introduction of low-priced biosimilar monoclonal antibodies, and surge in popularity of chimeric monoclonal antibodies in clinical development are expected to drive the growth of the market. Moreover, rise in R&D expenditure in the pharmaceutical & biopharmaceutical industry and increase in government support in infection control & management further boost the growth of the market. However, poor demand in underdeveloped countries is expected to restrain the growth of the monoclonal antibodies market.

 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285,
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Monoclonal Antibodies market is $146,642.0 million in 2020.

A. The forcast period for Monoclonal Antibodies market is 2021 to 2030

A. The market value of Monoclonal Antibodies market in 2021 is $1,62,479.3 million.

A. The base year is 2020 in Monoclonal Antibodies market

A. Top companies such as Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, Eli Lilly, and GlaxoSmithKline Plc held a high market position in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Human segment is the most influencing segment owing to increase in Rise in integration of advanced technology such as phage or yeast display, and transgenic mice, for human monoclonal antibodies generation, increase in usage for treatment of various chronic diseases, employment of advanced genetic engineering technology, and increase in government support in infection control & management

A. Increase in prevalence of cancer, increase in demand for cost-efficient biosimilar monoclonal antibodies, high demand for biologics, and increase in R&D activities in genomics coupled with the introduction of technologically advanced genetic platforms, such as next-generation sequencing are the major factors that drive the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to increase in number of initiatives and enhanced investments from governments for overall R&D of monoclonal antibodies and rise in number of product approvals. In addition, ongoing innovations in monoclonal antibodies, availability of advanced healthcare systems, and significant surge in demand for advanced healthcare facilities contribute toward the growth of the market.

A. Monoclonal antibody (mAb) therapy is a form of immunotherapy that utilizes monoclonal antibodies to attach mono specifically to specific proteins or cells.

A. Monoclonal antibodies are used to improve & suppress the immune responses in several medical conditions and to treat different diseases such as cardiovascular, cancer, and cerebrovascular diseases.

Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Monoclonal Antibodies Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers